Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MolVirX
- Development stage
- Preclinical
- Lead developer
- nanoigel
- Modality
- Small Molecules
01
Overview
MolVirX is a preclinical-stage small molecule therapeutic developed by nanoigel, consisting of a dynamic mixture of carboxylated cyanocobalamin (Vitamin B12) derivatives. It is designed as a broad-spectrum antiviral agent with concurrent nephroprotective properties. The drug's mechanism of action involves targeting the viral RNA-dependent RNA polymerase (RdRp) and specific RNA structures (aptamers) to inhibit viral replication. MolVirX has demonstrated activity against several viral pathogens, including the H1N1-09 strain of Influenza A, Newcastle disease virus (NDV), and the D52 strain of Infectious Bronchitis Virus (a coronavirus). Its nephroprotective effect is particularly relevant for nephropathogenic viral strains like IBV D52, which cause significant renal damage.
- Brand names
- MolVirX
- Other names
- MoLViRxnanoigel-RdRp-RNA aptamers-small molecule
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on MolVirX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MolVirX.